OTCMKTS:KHTRF Knight Therapeutics (KHTRF) Stock Price, News & Analysis $8.09 0.00 (0.00%) As of 10/30/2026 03:27 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Knight Therapeutics Stock (OTCMKTS:KHTRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Knight Therapeutics alerts:Sign Up Key Stats Today's Range$8.09▼$8.1250-Day Range$6.87▼$8.2852-Week Range$4.11▼$8.31Volume740 shsAverage Volume7,088 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Knight Therapeutics Inc. is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative prescription medicines. The company seeks products that address unmet medical needs, with an emphasis on pharmaceuticals and therapies that can be introduced through regulatory and commercial expertise rather than broad internal research operations. Knight markets and supports a portfolio of specialty medicines through direct commercial activities and partnerships. Its products and commercial arrangements have included therapies in areas such as oncology, rare diseases, hospital medicine and other specialty-care markets. The company also works with biotechnology and pharmaceutical developers to obtain regional rights to products for commercialization. Founded in 2014 by Jonathan Goodman, who previously founded Paladin Labs, Knight is headquartered in Montreal, Quebec. Its primary commercial focus has been Canada, along with selected markets in Latin America and other international jurisdictions through subsidiaries, partnerships and licensing agreements. Goodman serves as the company's president and chief executive officer.AI Generated. May Contain Errors. Read More Knight Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreKHTRF MarketRank™: 0.879895561355 of 5 starsKnight Therapeutics scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingKnight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKnight Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Knight Therapeutics' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Read more about Knight Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverKnight Therapeutics has a short interest ratio ("days to cover") of 119.61, which indicates bearish sentiment.Change versus previous monthShort interest in Knight Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News SentimentN/A News SentimentKnight Therapeutics has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Knight Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions24.85% of the stock of Knight Therapeutics is held by institutions.Read more about Knight Therapeutics' insider trading history. Receive KHTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KHTRF Stock News HeadlinesNotice of Knight Therapeutics’ Third Quarter 2026 Results Conference CallOctober 29, 2026 | financialpost.comFKnight Therapeutics Announces Regulatory Approval of NIKTIMVO® in BrazilOctober 6, 2026 | financialpost.comFElon's Terrifying Warning: America Is "1,000% Going Bankrupt"National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.November 2 at 1:00 AM | American Hartford Gold (Ad)Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada’s Top Growing CompaniesSeptember 25, 2026 | financialpost.comFKnight Therapeutics Announces Regulatory Submission of GEMTESA® in CanadaSeptember 15, 2026 | financialpost.comFKnight Therapeutics Announces Regulatory Submission of GEMTESA® in CanadaSeptember 15, 2026 | globenewswire.comKnight Therapeutics Inc KHTRFSeptember 10, 2026 | morningstar.comMKnight Therapeutics Announces Regulatory Approval of TAVALISSE® in ColombiaSeptember 1, 2026 | financialpost.comFSee More Headlines KHTRF Stock Analysis - Frequently Asked Questions How have KHTRF shares performed this year? Knight Therapeutics' stock was trading at $4.3765 at the beginning of 2026. Since then, KHTRF stock has increased by 84.9% and is now trading at $8.09. How do I buy shares of Knight Therapeutics? Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/02/2026Next Earnings (Estimated)11/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:KHTRF CIKN/A Webwww.knighttx.com Phone(514) 484-4483FaxN/AEmployees830Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:KHTRF) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredxIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't whole again un...USA Capital Gold | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
